In a monumental leap for transplant medicine, researchers have successfully altered the blood type of donor kidneys to a universal ‘O’ type using specialized enzymes. This groundbreaking achievement, culminating in the first human transplant of such an organ into a brain-dead recipient, promises to dramatically shorten wait times, particularly for underserved patient groups, and bring the concept of truly universal organs closer to reality.
The global organ shortage is a critical health crisis, leaving over 100,000 people in the United States alone waiting for a donor organ, with kidneys being the most needed. This dire situation is often compounded by the necessity of matching donor and recipient blood types, a barrier that significantly narrows the pool of viable organs and extends agonizing wait times for countless patients.
However, a recent scientific breakthrough is poised to revolutionize organ transplantation. Scientists have demonstrated the successful conversion of a donor kidney’s blood type to the universal type O before transplantation. This pioneering work involved using highly efficient enzymes to strip away specific blood group antigens, effectively making the organ compatible with a broader range of recipients.
The Blood Type Barrier in Organ Transplantation
Blood type compatibility is a fundamental requirement for safe organ transplantation. Individuals with type A or type B blood carry specific antigens that trigger an immune response if they receive an organ from a mismatched blood type. Type O blood, lacking these A and B antigens, is considered the universal donor, meaning Type O organs can theoretically be given to recipients of any ABO blood type.
Conversely, patients with type O blood can only receive organs from type O donors. This limitation disproportionately affects type O patients, who make up over half of kidney waitlists, forcing them to endure waiting periods that are often two to four years longer than other blood types, and tragically, many do not survive the wait, according to Reuters.
Historically, overcoming blood type incompatibility involved intensive desensitization therapies for the recipient, a demanding process that suppresses the immune system and requires days of treatment. This method is primarily feasible for transplants from living donors, further highlighting the need for a solution applicable to deceased donor organs.
A Molecular Breakthrough: Converting Blood Type A to O
The key to this paradigm shift lies in the development of specialized enzymes, often described as “molecular scissors.” A team from the University of British Columbia (UBC), led by Dr. Stephen Withers, a UBC professor emeritus of chemistry, and Dr. Jayachandran Kizhakkedathu, a UBC professor in the department of pathology and laboratory medicine, pioneered this enzymatic method. Their research focused on stripping away the sugars, or antigens, that define blood types from organ blood vessels.
As Dr. Withers explained, “it’s like removing the red paint from a car and uncovering the neutral primer.” Once the specific antigens, such as type A or B, are removed, “the immune system no longer sees the organ as foreign,” he added in a UBC news release. This effectively converts a Type A or Type B kidney into a Type O organ, making it universally compatible.
The journey to this breakthrough spans over a decade. The UBC team initially focused on making universal donor blood in the early 2010s. In 2019, they discovered two highly efficient enzymes capable of removing the sugar that defines type A blood, a discovery critical to making the entire concept feasible, as noted by Dr. Kizhakkedathu in a University of British Columbia news release.
First-in-Human Transplant: A Critical Step Forward
The pivotal moment came in late 2023 when international collaborators in China, utilizing the UBC-developed enzymes, successfully performed the first human transplant of a converted kidney. A type A kidney, initially rejected for transplantation, was converted to type O and then transplanted into a brain-dead recipient with type O blood, who possessed high levels of anti-A antibodies that would have otherwise led to certain rejection.
The results, published on October 3, 2025, in the journal Nature Biomedical Engineering, were highly encouraging. For two days, the enzyme-converted kidney functioned without any signs of hyperacute rejection, the rapid immune reaction that can destroy an incompatible organ within minutes. By the third day, some blood-type markers reappeared, triggering a mild immune reaction, but the damage observed was significantly less severe than in a typical mismatch. Researchers also saw signs that the body was beginning to tolerate the organ, a phenomenon known as accommodation.
This “first-in-human” experiment provided invaluable insights into how the converted organ interacts with the human immune system, information crucial for designing future clinical protocols to manage immune responses in living recipients, as reported in the study available through Nature Biomedical Engineering.
Impact and Future Implications
Addressing the Organ Shortage and Equity
The ability to convert donor organs to the universal type O holds immense promise for tackling the organ shortage. By removing blood type incompatibility as a barrier, the pool of usable organs from deceased donors could be significantly expanded, leading to a substantial reduction in patient wait times. This innovation is particularly vital for type O patients, who have historically faced the longest waits due to their restricted donor pool.
Beyond type O, this technology could also benefit other groups. For instance, individuals with type B blood, who are often black and Asian and represent a significant portion of kidney transplant candidates, also experience longer wait times. While genotyping technology is exploring ways to identify specific A2 subgroup donors for B recipients, enzyme conversion offers a more universal solution, potentially addressing health inequities in transplantation.
The Road Ahead: Clinical Trials and Beyond
With the success of the first human transplant in a brain-dead model, the next major hurdle is obtaining regulatory approval for clinical trials involving living recipients. Avivo Biomedical, a UBC spin-off company associated with the researchers, is leading the development of these enzymes for transplant application. The long-term vision extends beyond organs to include the creation of universal donor blood on demand for transfusion medicine, further broadening the impact of this technology.
Dr. Withers articulated the profound significance of this work, stating, “This is what it looks like when years of basic science finally connect to patient care. Seeing our discoveries edge closer to real-world impact is what keeps us pushing forward,” a sentiment echoed in multiple reports, including a University of British Columbia news release.
This breakthrough represents a monumental stride towards a future where blood type is no longer a limiting factor in organ transplantation, offering renewed hope and a chance at life for thousands awaiting a critical, life-saving organ.
